Skip to main content
Erschienen in: The European Journal of Health Economics 1/2005

01.03.2005 | Original Papers

The cost-effectiveness of human papillomavirus screening for cervical cancer

A review of recent modelling studies

verfasst von: Jeremy Holmes, Lindsay Hemmett, Susan Garfield

Erschienen in: The European Journal of Health Economics | Ausgabe 1/2005

Einloggen, um Zugang zu erhalten

Abstract

We compared findings from recent studies modelling the cost-effectiveness of screening for cervical cancer using human papillomavirus (HPV) testing and alternative strategies. Data were standardized to facilitate comparison of costs per life year or costs per QALY gained in six studies. Absolute changes in costs, life years and QALYs for each strategy were normalized to a comparison with no screening. Costs were standardized to US$ in 2000 values. Most models assume screening starts at age 18 or 20 years. Assumed prevalence of HPV ranges from 10% for those aged 18 years to 20% for those aged 20–25 years and drops substantially after age 30. All except one model assume sensitivity to LSIL of 83% or higher. Two models distinguish the increasing specificity of HPV testing in older age groups (up to 95% for LSIL in women aged 55 years or older). All the models include consultation costs as well as screening and treatment costs, but costs for follow-up diagnosis and treatment vary considerably. Two models also include patient time costs. Despite these differences all strategies involving HPV testing have cost per quality-adjusted life-year (QALY) ratios in the range of $12,400–$16,600. Costs per life year vary more widely, the highest being $19,246 (annual screening with liquid cytology and HPV). However, excluding strategies using liquid cytology, the highest costs per life year for a strategy including HPV testing are under $14,000 (simultaneous conventional cytology and HPV every two years). The cost per life year for HPV testing alone triennially is lower than for Pap smear testing alone biennially. Costs per QALY are generally lower than costs per life year (given the reported modelling assumptions and settings). Even with inclusion of patient costs, no strategies involving HPV testing cost more than $16,600 per QALY. Adoption of the ACOG guidelines to include HPV testing with cytology as a screening option for women aged 30 years or older therefore appears to be cost-effective.
Literatur
1.
Zurück zum Zitat Anonymous (2003) Clinical management guidelines for obstetrician-gynecologists. ACOG practice bulletin no. 45. Obstet Gynaecol 102:417–427CrossRef Anonymous (2003) Clinical management guidelines for obstetrician-gynecologists. ACOG practice bulletin no. 45. Obstet Gynaecol 102:417–427CrossRef
2.
Zurück zum Zitat Saslow D et al. (2002) American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 52:342–362PubMed Saslow D et al. (2002) American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 52:342–362PubMed
3.
Zurück zum Zitat Association of Reproductive Health Professionals (2004) Advances in cervical cancer protection. Clin Proc, Sept 2003 Association of Reproductive Health Professionals (2004) Advances in cervical cancer protection. Clin Proc, Sept 2003
4.
Zurück zum Zitat Wright TC et al. (1998) Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. Am J Obstet Gynaecol 178:962–966 Wright TC et al. (1998) Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. Am J Obstet Gynaecol 178:962–966
5.
Zurück zum Zitat Mandelblatt JS et al. (2002) Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 287:2372–2381CrossRefPubMed Mandelblatt JS et al. (2002) Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 287:2372–2381CrossRefPubMed
6.
Zurück zum Zitat Cuzick J, Sasieni P (1997) Estimates of the cost impact of introducing human papillomavirus testing into a cervical screening programme. In: Franco, Monsonego (eds) New developments in cervical cancer screening & prevention. Oxford: Blackwell Cuzick J, Sasieni P (1997) Estimates of the cost impact of introducing human papillomavirus testing into a cervical screening programme. In: Franco, Monsonego (eds) New developments in cervical cancer screening & prevention. Oxford: Blackwell
7.
Zurück zum Zitat Goldie S, Kim J, Wright T (2004) Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynaecol 103:619–631 Goldie S, Kim J, Wright T (2004) Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynaecol 103:619–631
8.
Zurück zum Zitat Cuzick J et al. (1999) Assessing effectiveness, costs and cost-effectiveness of cervical cancer screening and HPV testing. Health Technol Assess 3:95–109 Cuzick J et al. (1999) Assessing effectiveness, costs and cost-effectiveness of cervical cancer screening and HPV testing. Health Technol Assess 3:95–109
9.
Zurück zum Zitat Goldie S (2002) Health economics and cervical cancer prevention: a global perspective. Virus Res 89:301–309CrossRefPubMed Goldie S (2002) Health economics and cervical cancer prevention: a global perspective. Virus Res 89:301–309CrossRefPubMed
10.
Zurück zum Zitat Kim J, Wright T, Goldie S (2002) Cost-effectiveness and alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 287:2382–2390CrossRefPubMed Kim J, Wright T, Goldie S (2002) Cost-effectiveness and alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 287:2382–2390CrossRefPubMed
11.
Zurück zum Zitat Maxwell GL et al. (2002) Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries. Obstet Gynaecol 100:740–748CrossRef Maxwell GL et al. (2002) Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries. Obstet Gynaecol 100:740–748CrossRef
12.
Zurück zum Zitat Mittendorf T, Schulenburg JMG von der, Petry K, Iftner T (2003) Economic evaluation of human papillomavirus screening in Germany. Eur J Health Econ 4:209–215CrossRef Mittendorf T, Schulenburg JMG von der, Petry K, Iftner T (2003) Economic evaluation of human papillomavirus screening in Germany. Eur J Health Econ 4:209–215CrossRef
13.
Zurück zum Zitat Ballegooijen M van et al. (1997) Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness. Br J Cancer 76:651–657PubMed Ballegooijen M van et al. (1997) Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness. Br J Cancer 76:651–657PubMed
14.
Zurück zum Zitat Linos A, Riza E (2000) Comparisons of cervical cancer screening programmes in the European Union. Eur J Cancer 36:2260–2265CrossRefPubMed Linos A, Riza E (2000) Comparisons of cervical cancer screening programmes in the European Union. Eur J Cancer 36:2260–2265CrossRefPubMed
15.
Zurück zum Zitat Clavel C et al. (2001) Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 89:1616–1623CrossRef Clavel C et al. (2001) Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 89:1616–1623CrossRef
16.
Zurück zum Zitat Salzmann P, Kerlikowske K, Phillips K (1997) Cost effectiveness of extending screening mammography guidelines to include women 40–49 years of age. Ann Intern Med 127:955–965PubMed Salzmann P, Kerlikowske K, Phillips K (1997) Cost effectiveness of extending screening mammography guidelines to include women 40–49 years of age. Ann Intern Med 127:955–965PubMed
17.
Zurück zum Zitat Sherlaw-Johnson C & Philips Z (2004) An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. BR J Cancer 91:84–91CrossRefPubMed Sherlaw-Johnson C & Philips Z (2004) An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. BR J Cancer 91:84–91CrossRefPubMed
18.
Zurück zum Zitat Annual country-specific inflation rates taken from OECD: Wages, Costs, Unemployment & Inflation, E 073 Annual country-specific inflation rates taken from OECD: Wages, Costs, Unemployment & Inflation, E 073
Metadaten
Titel
The cost-effectiveness of human papillomavirus screening for cervical cancer
A review of recent modelling studies
verfasst von
Jeremy Holmes
Lindsay Hemmett
Susan Garfield
Publikationsdatum
01.03.2005
Verlag
Springer-Verlag
Erschienen in
The European Journal of Health Economics / Ausgabe 1/2005
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-004-0254-1

Weitere Artikel der Ausgabe 1/2005

The European Journal of Health Economics 1/2005 Zur Ausgabe